富蘭克林坦伯頓全球投資系列-生技領航基金美元B(acc)股(停止銷售)
24.31美元0.26(1.08%)
2022/12/20更新
本基金之投資目標在於資本增值。 本基金主要投資位於美國以及其他國家的生物科技公司以及發現研究公司之股權證券,以及小部份延伸投資位於全球各地公司所發行的各種債權證券。
大型 | |||
---|---|---|---|
中型 | |||
小型 | |||
價值型 | 均衡型 | 增長型 |
Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.
Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co. Ms. Lam has a Ph.D degree.
Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.